These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 19151906)

  • 21. Domain-specific improvement of cognition on memantine in patients with Alzheimer's disease treated with rivastigmine.
    Riepe MW; Adler G; Ibach B; Weinkauf B; Tracik F; Gunay I
    Dement Geriatr Cogn Disord; 2007; 23(5):301-6. PubMed ID: 17356273
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rivastigmine: a placebo controlled trial of twice daily and three times daily regimens in patients with Alzheimer's disease.
    Feldman HH; Lane R;
    J Neurol Neurosurg Psychiatry; 2007 Oct; 78(10):1056-63. PubMed ID: 17353259
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy of rivastigmine in subjects with moderately severe Alzheimer's disease.
    Burns A; Spiegel R; Quarg P
    Int J Geriatr Psychiatry; 2004 Mar; 19(3):243-9. PubMed ID: 15027039
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An efficacy and safety analysis of Exelon in Alzheimer's disease patients with concurrent vascular risk factors.
    Kumar V; Anand R; Messina J; Hartman R; Veach J
    Eur J Neurol; 2000 Mar; 7(2):159-69. PubMed ID: 10809936
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Does serotonin augmentation have any effect on cognition and activities of daily living in Alzheimer's dementia? A double-blind, placebo-controlled clinical trial.
    Mowla A; Mosavinasab M; Haghshenas H; Borhani Haghighi A
    J Clin Psychopharmacol; 2007 Oct; 27(5):484-7. PubMed ID: 17873681
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Changes in metabolite ratios after treatment with rivastigmine in Alzheimer's disease: a nonrandomised controlled trial with magnetic resonance spectroscopy.
    Modrego PJ; Pina MA; Fayed N; Díaz M
    CNS Drugs; 2006; 20(10):867-77. PubMed ID: 16999455
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rivastigmine for cognitive impairment after spontaneous subarachnoid haemorrhage: a pilot study.
    Wong GK; Wong R; Mok V; Wong A; Fan D; Leung G; Chan A; Poon WS
    J Clin Pharm Ther; 2009 Dec; 34(6):657-63. PubMed ID: 20175798
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Disease stage in Alzheimer disease and treatment effects of rivastigmine.
    Kurz A; Farlow M; Quarg P; Spiegel R
    Alzheimer Dis Assoc Disord; 2004; 18(3):123-8. PubMed ID: 15494617
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Response of patients with Alzheimer disease to rivastigmine treatment is predicted by the rate of disease progression.
    Farlow MR; Hake A; Messina J; Hartman R; Veach J; Anand R
    Arch Neurol; 2001 Mar; 58(3):417-22. PubMed ID: 11255445
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial.
    Rösler M; Anand R; Cicin-Sain A; Gauthier S; Agid Y; Dal-Bianco P; Stähelin HB; Hartman R; Gharabawi M
    BMJ; 1999 Mar; 318(7184):633-8. PubMed ID: 10066203
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Savings in the cost of caring for patients with Alzheimer's disease in Canada: an analysis of treatment with rivastigmine.
    Hauber AB; Gnanasakthy A; Mauskopf JA
    Clin Ther; 2000 Apr; 22(4):439-51. PubMed ID: 10823365
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Efficacy of Transdermal Rivastigmine in Mild to Moderate Alzheimer's Disease with Concomitant Small Vessel Cerebrovascular Disease: Findings from an Open-Label Study.
    Yatawara C; Zailan FZ; Chua EV; Lim LLH; Silva E; Wang JS; Ng A; Ng KP; Kandiah N
    Clin Interv Aging; 2021; 16():301-309. PubMed ID: 33642856
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of Idalopirdine as Adjunct to Cholinesterase Inhibitors on Change in Cognition in Patients With Alzheimer Disease: Three Randomized Clinical Trials.
    Atri A; Frölich L; Ballard C; Tariot PN; Molinuevo JL; Boneva N; Windfeld K; Raket LL; Cummings JL
    JAMA; 2018 Jan; 319(2):130-142. PubMed ID: 29318278
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A systematic review of the clinical effectiveness of donepezil, rivastigmine and galantamine on cognition, quality of life and adverse events in Alzheimer's disease.
    Takeda A; Loveman E; Clegg A; Kirby J; Picot J; Payne E; Green C
    Int J Geriatr Psychiatry; 2006 Jan; 21(1):17-28. PubMed ID: 16323253
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy of rivastigmine in Alzheimer's disease patients with rapid disease progression: results of a meta-analysis.
    Farlow MR; Small GW; Quarg P; Krause A
    Dement Geriatr Cogn Disord; 2005; 20(2-3):192-7. PubMed ID: 16088144
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer's disease over a 2-year period.
    Bullock R; Touchon J; Bergman H; Gambina G; He Y; Rapatz G; Nagel J; Lane R
    Curr Med Res Opin; 2005 Aug; 21(8):1317-27. PubMed ID: 16083542
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of rivastigmine treatment on the neuropsychiatric and behavioral disturbances of nursing home residents with moderate to severe probable Alzheimer's disease: a 26-week, multicenter, open-label study.
    Cummings JL; Koumaras B; Chen M; Mirski D;
    Am J Geriatr Pharmacother; 2005 Sep; 3(3):137-48. PubMed ID: 16257816
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Cholinergic therapy of Alzheimer's disease and its effect on health and quality of life of caregivers to the patients].
    Kolykhalov IV; Rassadina GA; Gavrilova SI; Gerasimov NP
    Zh Nevrol Psikhiatr Im S S Korsakova; 2010; 110(5 Pt 1):33-8. PubMed ID: 21322823
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Preserved cognitive function after 12 months of treatment with rivastigmine in mild Alzheimer's disease in comparison with untreated AD and MCI patients.
    Almkvist O; Darreh-Shori T; Stefanova E; Spiegel R; Nordberg A
    Eur J Neurol; 2004 Apr; 11(4):253-61. PubMed ID: 15061827
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Brain metabolic and clinical effects of rivastigmine in Alzheimer's disease.
    Potkin SG; Anand R; Fleming K; Alva G; Keator D; Carreon D; Messina J; Wu JC; Hartman R; Fallon JH
    Int J Neuropsychopharmacol; 2001 Sep; 4(3):223-30. PubMed ID: 11602028
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.